Please login to the form below

Not currently logged in
Email:
Password:

SMC fails to recommend Roche’s Perjeta

Says drug is not a cost-effective option in breast cancer
Scottish flag

The Scottish Medicines Consortium (SMC) has not recommended Roche's Perjeta for use in the treatment of unresectable breast cancer.

The news comes after Perjeta (pertuzumab) was resubmitted for consideration under the end of life/orphan medicine process for adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer.

The drug was proposed to be used in combination with trastuzumab and docetaxel for those who had not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

Roche's Perjeta pertuzumab 

Perjeta demonstrated "phenomenal" results at the European Society for Medical Oncology (ESMO) meeting in September

The SMC said the decision was due to Roche's lack of 'sufficiently robust economic analysis' and justification of the treatment's cost in relation to its health benefits.

Perjeta has previously turned down for NHS reimbursement in England due to negative guidance from the National Institute for Health and Care Excellence (NICE), although the drug is available via the Cancer Drugs Fund.

Eylea, Afinitor, Daklinza, Yervoy and Onglyza all get thumbs up

Elsewhere, the SMC backed reimbursement for several drugs within NHS Scotland.

Bayer's Eylea (aflibercept) has been accepted for restricted use in adults with visual impairment due to diabetic macular oedema (DMO). However, the SMC restricted use of the drug to adults with best-corrected visual acuity (BCVA) 75 Early Treatment Diabetic Retinopathy Study (ETDRS) letters or less at baseline.

Afinitor (everolimus), marketed by Novartis, was backed for patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy.

Bristol-Myers Squibb (BMS) had two drugs recommended by the SMC. Daklinza (daclatasvir) was accepted for use in combination with other products for the treatment of chronic hepatitis C virus (HCV) infection in adults, while Yervoy (ipilimumab) was also given the go ahead for the treatment of advanced melanoma in adults.

However, the SMC restricted use of Daklinza to patients with significant fibrosis (Metavir scores F3-F4) or compensated cirrhosis.

The SMC also recommended the use of AstraZeneca's Onglyza (saxagliptin) in adult patients with type 2 diabetes mellitus to improve glycaemic control as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Article by
Kirstie Pickering

11th November 2014

From: Sales, Healthcare

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

01 PME-APR21 Cover.jpg
Virtual congresses: video thrilled the cardio tsar
Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?
The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.
Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....

Infographics